Goldman Sachs keeps Brent oil forecast intact
'Increasing pressure on Russia and Iran sanctioned oil supply poses an upside risk to our price forecast, especially given the faster-than-expected normalisation in spare capacity,' the investment bank said in a note on Sunday.
However, Goldman flagged a downside risk to its 800,000 barrels per day average annual demand growth forecast in 2025 and 2026 due to the increase in US tariff rates, threats of additional secondary tariffs and weak US economic activity data.
The weaker data 'suggests that the US economy is now growing at a below-potential pace', which the bank's economists' feel has increased the chance of a recession in the next 12 months, the note said.
The Organisation of the Petroleum Exporting Countries and its allies such as Russia (Opec+), agreed on Sunday to raise oil production by 547,000 barrels per day for September, the latest in a series of accelerated output hikes to regain market share.
'While Opec+ policy remains flexible, we assume Opec+ will keep its production quota unchanged after September as we expect the pace of builds in the Organisation for Economic Co-operation and Development's commercial stocks to accelerate and seasonal demand tailwinds to fade away,' Goldman said.
Brent crude futures were trading at US$69.27 a barrel, while US West Texas Intermediate crude was at US$66.96 a barrel.
'We continue to see limited risk of large disruptions in Russia supply given the large volumes of Russian imports, the possibility for deepening price discounts to maintain demand and continuing reported eagerness of the key buyers – China and India,' analysts at Goldman Sachs said.
Indian state refiners have stopped buying Russian oil in the past week as discounts narrowed this month and US President Donald Trump warned countries not to purchase oil from Moscow, industry sources said. — Reuters
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Straits Times
an hour ago
- New Straits Times
Brexit's parallels with Trump tariffs tell a tale
In figuring out why the United States tariff shock hasn't sent the economy or financial world into a tailspin, Britain's exit from the European Union trade bloc provides something of a playbook — and without a particularly happy ending. Aside from vast differences in economic scale and global reach, the two episodes bear some comparison in how they upended years of deeply integrated free trade and possibly in how business, the economy at large and financial markets reacted. The 2016 Brexit referendum and Trump's tariffs this year were each widely billed as economic shocks that would send the financial world into paroxysms. They didn't, at least not at the outset. To be sure, both were followed by dramatic downward lurches in the two countries' currencies. But, to some extent, the steep drop in sterling after the referendum vote and the dollar's plunge on President Donald Trump's tariff plan this year helped offset some of the wider impact, at least on stock markets that are loaded with global firms with outsized foreign revenue. More broadly, however, the difficulty in isolating their immediate net impact means no "big bang" economic crisis unfolds to prove critics right, even if their enduring legacy turns out to be a slow burn of economic potential and lost output, often obscured by multiple other crosswinds. In Britain's case, the seismic effects of the Covid-19 pandemic distorted any attempt to easily assess Brexit when it actually happened. Tortuous negotiations with the EU meant the UK's departure eventually occurred on the eve of the health crisis in 2020 and the new trade rules did not come into force until a year later. But in the four years between the referendum surprise and the pandemic, the UK economy never entered a recession nor recorded a negative quarterly GDP print — confounding pro-EU supporters at the time and bolstering the Brexit lobby. Emerging from the twin hits, however, the economy has almost flatlined since. What's more, it's taken more than eight years for the pound's effective exchange rate to recover its pre-referendum levels. Few mainstream economists now doubt that Brexit has taken a serious toll on the UK economy. One academic study by a number of Bank of England economists earlier this year concluded that uncertainty following the referendum resulted in little change in goods exports and imports before the exit was finalised. But after the new rules hit, UK imports fell three per cent and overall exports fell 6.4 per cent, largely because of the 13 per cent hit in exports to the EU. While this slump seems relatively modest compared with the official forecasts of the longer-term hit, the pain has been borne disproportionately by small businesses. And the cumulative damage to London and the service sector over the next 10 years continues to worry the City. The US tariff story is of a completely different order, of course, as it will reverberate across the world economy. But there are some parallels, not least in certain aspects of the market reactions and the initial resilience. Economists estimate that the tariffs could lop anywhere from 0.5 per cent to one per cent off US gross domestic product over time. That's a US$150 billion to US$300 billion hit, which, though painful, would not be an instant crisis for an economy that's growing at a roughly two per cent annualised rate, where imported goods represent just 11 per cent of GDP and where tech and AI trends are generating considerable tailwinds. But as former White House economic adviser Jason Furman said in a New York Times essay last week, the tariff damage is likely not a one-off hit. The loss of 0.5 per cent of GDP, he argued, is "the equivalent of every household in America taking around US$1,000 and lighting it on fire, then doing it again every year. Forever." In the end, the main point of the British comparison is to show how extreme partisan arguments on the pros or cons of such giant economic policy changes don't necessarily get resolved cleanly in adaptive, hardy and hyper-complex economies. The latest YouGov opinion poll shows 56 per cent of Britons now think it was wrong to leave the EU, some nine years after their narrow vote to leave. The jury on Trump's tariffs is still out.
The Sun
2 hours ago
- The Sun
Trump proposes 250% tariff on imported pharmaceuticals
WASHINGTON: US President Donald Trump revealed plans to impose tariffs on imported pharmaceuticals that could escalate to 250%, alongside new duties on foreign semiconductors. The move aims to push for domestic manufacturing of critical goods. 'We'll be putting (an) initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150 percent,' Trump said in an interview on CNBC. 'And then it's going to go to 250 percent because we want pharmaceuticals made in our country.' The announcement follows earlier tariffs on steel, aluminum, and auto parts, part of Trump's broader trade strategy targeting imports deemed a national security concern. The administration has conducted investigations into pharmaceuticals and semiconductors, signaling upcoming policy shifts. Trump also indicated an imminent increase in tariffs on Indian imports, citing the country's purchases of Russian oil. 'I expect to raise the US tariff on Indian imports very substantially over the next 24 hours,' he said. The proposed pharmaceutical tariffs mark a significant escalation in trade measures, potentially disrupting global supply chains. Industry analysts warn of higher drug prices, while supporters argue it will strengthen US self-sufficiency. - AFPpix
The Sun
3 hours ago
- The Sun
Malaysia sets sights on becoming Asean pharmaceutical and healthcare hub
KUALA LUMPUR: Malaysia is setting its sights on becoming a halal pharmaceutical and healthcare hub for Asean, leveraging partnerships with India's booming pharma sector as industry leaders prepare for the Second Malaysia Pharma and Healthcare Expo (MPHC 2025) in October. The expo, to be held at the World Trade Centre Kuala Lumpur from Oct 7 to 9, is expected to attract over 100 companies, up from 70 last year, alongside policymakers, researchers and investors across Asean, India, Australia and South Korea. Organisers say the event will spotlight innovations in halal-certified drugs, active pharmaceutical ingredients (APIs), biotech, regenerative medicine, telehealth and AI-driven diagnostics. Malaysia-India Business Council general secretary Datuk Surendran Menon said trade between Malaysia and India stood at US$20 billion (RM84.6 billion) in 2024, but pharmaceuticals made up just US$96–$104 million of that figure, a sign of significant untapped potential. 'India is known as the pharma of the world, while Malaysia offers halal regulation expertise and a strategic Asean strong potential in contract manufacturing, technology transfer and joint R&D, especially in halal pharmaceuticals and vaccines,' Surendran told reporters at a media briefing today. He said Malaysia imports over 70% of its pharmaceutical products, and the government's national pharmaceutical policy is pushing for greater domestic production, a move that could entice Indian firms seeking to expand into Asean markets. He also pointed to India's own 200 million-strong Muslim population as an untapped market for halal pharma products manufactured in Malaysia. 'Even if we tap just 50 million of that halal market in India, it's far larger than our domestic market here. Halal-certified medicines made in Malaysia could be exported not just across Asean but also back into India itself,' he said. This strategy, he added, would allow two-way investment flows, Indian companies bringing R&D and cost efficiencies to Malaysia, while Malaysian firms could set up manufacturing or joint ventures in India. Asean-India Economic Council chairman Datuk Ramesh Kodammal said Malaysia stands to benefit from India's US$50 billion pharmaceutical export industry, particularly as Asean and India review their free trade agreement, which has been in place for 11 years. 'If we work closely with India, we will have a lot of benefit,' he said, adding Malaysia has a great advantage of re-exporting with these Indian companies for the Asean market a huge market of 700 million people. Ramesh confirmed 40 Indian companies are slated to participate in MPHC 2025, alongside Asean, Australian and South Korean firms.
